A detailed history of Sumitomo Mitsui Ds Asset Management Company, LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Ds Asset Management Company, LTD holds 152,398 shares of GILD stock, worth $14.1 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
152,398
Previous 164,139 7.15%
Holding current value
$14.1 Million
Previous $11.3 Million 13.44%
% of portfolio
0.14%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$66.59 - $83.99 $781,833 - $986,126
-11,741 Reduced 7.15%
152,398 $12.8 Million
Q2 2024

Jul 30, 2024

BUY
$63.15 - $72.88 $790,511 - $912,311
12,518 Added 8.26%
164,139 $11.3 Million
Q1 2024

May 02, 2024

BUY
$71.58 - $87.29 $391,184 - $477,039
5,465 Added 3.74%
151,621 $11.1 Million
Q4 2023

Feb 01, 2024

BUY
$73.27 - $83.09 $165,663 - $187,866
2,261 Added 1.57%
146,156 $11.8 Million
Q3 2023

Oct 30, 2023

BUY
$73.94 - $80.67 $315,797 - $344,541
4,271 Added 3.06%
143,895 $10.8 Million
Q2 2023

Aug 04, 2023

BUY
$76.01 - $86.7 $1.9 Million - $2.17 Million
25,010 Added 21.82%
139,624 $10.8 Million
Q1 2023

May 02, 2023

BUY
$77.31 - $88.08 $383,689 - $437,141
4,963 Added 4.53%
114,614 $9.51 Million
Q4 2022

Jan 26, 2023

SELL
$62.32 - $89.47 $594,158 - $853,006
-9,534 Reduced 8.0%
109,651 $0
Q3 2022

Oct 19, 2022

BUY
$59.54 - $68.01 $391,177 - $446,825
6,570 Added 5.83%
119,185 $7.35 Million
Q2 2022

Jul 13, 2022

BUY
$57.72 - $65.01 $310,014 - $349,168
5,371 Added 5.01%
112,615 $6.96 Million
Q1 2022

Apr 19, 2022

BUY
$57.92 - $72.58 $206,368 - $258,602
3,563 Added 3.44%
107,244 $6.38 Million
Q4 2021

Jan 20, 2022

BUY
$64.88 - $73.64 $179,717 - $203,982
2,770 Added 2.74%
103,681 $7.53 Million
Q3 2021

Oct 15, 2021

SELL
$67.69 - $73.03 $1.97 Million - $2.13 Million
-29,128 Reduced 22.4%
100,911 $7.05 Million
Q2 2021

Jul 19, 2021

BUY
$63.47 - $69.35 $73,180 - $79,960
1,153 Added 0.89%
130,039 $8.95 Million
Q1 2021

May 07, 2021

BUY
$60.0 - $68.46 $343,920 - $392,412
5,732 Added 4.65%
128,886 $8.33 Million
Q4 2020

Feb 02, 2021

SELL
$56.65 - $64.55 $65,883 - $75,071
-1,163 Reduced 0.94%
123,154 $7.17 Million
Q3 2020

Oct 29, 2020

BUY
$62.1 - $78.08 $185,492 - $233,224
2,987 Added 2.46%
124,317 $7.86 Million
Q2 2020

Aug 12, 2020

SELL
$72.34 - $84.0 $553,039 - $642,180
-7,645 Reduced 5.93%
121,330 $9.34 Million
Q1 2020

Apr 21, 2020

SELL
$62.63 - $80.22 $471,666 - $604,136
-7,531 Reduced 5.52%
128,975 $9.64 Million
Q4 2019

Jan 24, 2020

SELL
$61.62 - $67.78 $39,868 - $43,853
-647 Reduced 0.47%
136,506 $8.87 Million
Q3 2019

Oct 16, 2019

BUY
$62.51 - $69.0 $1.3 Million - $1.43 Million
20,773 Added 17.85%
137,153 $8.69 Million
Q2 2019

Aug 13, 2019

SELL
$61.87 - $69.38 $1.31 Million - $1.47 Million
-21,132 Reduced 15.37%
116,380 $7.86 Million
Q1 2019

May 07, 2019

BUY
$62.53 - $70.05 $705,588 - $790,444
11,284 Added 8.94%
137,512 $8.94 Million
Q4 2018

Jan 25, 2019

SELL
$60.54 - $79.0 $236,771 - $308,969
-3,911 Reduced 3.01%
126,228 $7.9 Million
Q3 2018

Oct 15, 2018

BUY
$71.28 - $78.92 $2.75 Million - $3.05 Million
38,633 Added 42.22%
130,139 $10 Million
Q2 2018

Jul 31, 2018

BUY
$64.88 - $75.68 $49,308 - $57,516
760 Added 0.84%
91,506 $6.48 Million
Q1 2018

Apr 25, 2018

SELL
$72.84 - $88.8 $261,349 - $318,614
-3,588 Reduced 3.8%
90,746 $6.84 Million
Q4 2017

Jan 25, 2018

SELL
$71.15 - $83.52 $394,099 - $462,617
-5,539 Reduced 5.55%
94,334 $6.76 Million
Q3 2017

Oct 27, 2017

BUY
$72.11 - $85.47 $7.2 Million - $8.54 Million
99,873
99,873 $8.09 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Sumitomo Mitsui Ds Asset Management Company, LTD Portfolio

Follow Sumitomo Mitsui Ds Asset Management Company, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.